European Medicines Agency: more protected with vaccine boosters other than the first dose

• Vaccine, Iss: efficacy remains high, 94.3% against the risk of deaths

• Jaws: Merck Pill Decreases Risk of Death and Hospitalization

Share

October 21, 2021 Not only would they work, but the immune response would be more powerful. Thus the European Medicines Agency on the administration - for the second or third dose - of a vaccine other than the first. They are among the data exposed by the EMA in Brussels, based on the studies that analyzed the data of the last few months.

But the press conference is also an opportunity for a dive into the so-called

- the theory according to which by letting the virus circulate freely, the population of a country would achieve immunity: tranchant the Agency's judgment: "With almost five millions of deaths worldwide, the human cost of natural immunity is not tolerable. " 

That will be the date on which the EMA will decide on the booster dose of the anti-Covid Spikevax vaccine (by Moderna), for people over 12 years of age, six months after the second dose.

While it is underway in the meantime, the review continues - the so-called rolling review - for the use of the Pfizer vaccine on children between 5 and 11 years old. 

Next week, the Agency will start analyzing the Merck pill (Molnupiravir): it would be the first oral antiviral drug, a work that should be completed within 2-3 months.